To Evaluate an MRI-based Optimized Prostate Cancer Diagnostic Pathway Powered by Artificial Intelligence

Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 8, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to diagnose prostate cancer using advanced technology. Specifically, researchers want to see if an artificial intelligence (AI) program can review MRI images of the prostate just as well as an experienced radiologist can. About 368 men who have been recommended for a prostate biopsy will have their MRI scans examined by both the AI system and a radiologist. The findings from these reviews will help guide doctors in creating personalized biopsy plans. The accuracy of both methods will be checked against results from a specific type of biopsy that combines MRI and ultrasound images.

To participate in this study, men must be at least 18 years old and have been recommended for a prostate biopsy. They also need to have MRI images that can be reviewed by both the AI and the radiologist. It’s important to note that men who cannot undergo a prostate biopsy or who do not complete the procedure will not be eligible for this trial. Those who participate can expect their MRI results to be reviewed by both the AI and a radiologist, which may help improve the accuracy of prostate cancer detection.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients recommended for prostate biopsy for diagnosis or re-assessment.
• • Men at least 18 years or over
• • Patients with prostate MRI image eligible for radiologist review and AI review.
• • Patient Informed Consent is signed.
• Exclusion Criteria:
• • Patient contraindicated to prostate biopsy
• • Patient failed to complete the biopsy procedure